![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
June 11, 2025
The group is recognizing Dr. Schiller for her sustained commitment to mentoring early- and mid-career investigators in cancer medicine and in ECOG-ACRIN
June 11, 2025
The changes broaden eligibility and clarify treatment planning details in this phase 2 trial testing daratumumab-hyaluronidase to eliminate minimal residual disease after initial chemotherapy
June 11, 2025
Researchers with the ECOG-ACRIN Cancer Research Group presented a number of research findings at the 2025 ASCO Annual Meeting
June 11, 2025
Summaries and links to timely information about research results presented at medical meetings, recognition of research leaders, and more
April 24, 2025
An update on the Group's activity; a new Central Biorepository and Pathology Facility director; a preview of key Group Meeting sessions
April 24, 2025
The changes broaden eligibility for this cancer care delivery study, which aims to improve medication adherence for patients with breast cancer
April 24, 2025
These two trials are open and enrolling adolescent and young adult survivors and patients with cancer
April 24, 2025
April 24, 2025
Summaries of recently published ECOG-ACRIN research results
April 24, 2025
Summaries and links to timely information about research results presented at medical meetings, recognition of research leaders, and more
March 21, 2025
An update on the NCTN Grant; upcoming Group Meeting highlights; a perspective on the mistrust of science
March 21, 2025
The changes significantly broaden eligibility and clarify key details in this phase 3 trial exploring whether adding radiation therapy to standard immunotherapy will improve survival in patients with stable disease after initial treatment